Merck & Co., Inc.

Key Statistics

Recent News

• What Could Push JNJ Stock Higher From Here? Trefis

  While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The In

• Merck (MRK) Stock After 53% One-Year Gain Is DCF Signaling Further Upside Potential Simply Wall St.

  For investors considering whether Merck at around US$120.76 still offers value or whether most of the upside is already reflected in the price, this article walks through the key checks investors ofte

• Sector Update: Healthcare Stocks Softer Late Afternoon MT Newswires

  Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State St

• JNJ Raised the Bar: So Why Is the Stock Standing Still? Trefis

  Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

• The Catch Hiding In Eli Lilly Stock's Growth Story Trefis

  Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

• Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? Zacks

  BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

• Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views? Zacks

  Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this hig

• PAHC Stock: What's Driving Phibro's Animal Health Growth Zacks

  Phibro Animal Health unit drove 74% of fiscal 2025 revenue, fueled by MFA, vaccines and global expansion, helping offset pressure in other businesses.